top of page

TREATMENTS

Appearance Medicine
Body Treatments
Products

Cosmetic Medicine Brands. Full Consumer Print Mandatories.


1.Botox® is a prescription medicine for the treatment of frown lines , horizontal forehead lines and crow’s feet round the eyes.
Botox® has risks and benefits. Ask your doctor if Botox is right for you. If you have side effects, see your doctor. You will need to pay for Botox® and clinic fees will apply. For details on precautions & side effects consult your healthcare professional or the Consumer Medicine Information (CMI) at www.medsafe.govt.nz . Botox® treatment lasts about 4 months and further courses of treatment may be necessary. Should only be administered by trained medical professionals. (contains botulinum toxin A 50,100 & 200 units) Allergan (NZ) Limited, Auckland.

2. Restylane® is a gel containing hyaluronic acid and lidocaine that is injected by a healthcare professional into or below the skin to
smooth facial wrinkles and enhance lips by restoring volume and fullness. Restylane is a Class III medical device and has risks and benefits. Restylane® treatment may result in some redness, swelling, pain or tenderness, itching and/or bruising which may last a few days. Inflammatory reactions can begin up to two to four weeks after treatment in rare cases. See your healthcare professional if any side effects concern you. Exposure to excessive sunlight or extreme cold should be avoided until redness or swelling has resolved.
Restylane® should not be used in an area where there is a nonresorbable implant or in irritated or infected skin, Restylane® should not be used in people taking blood thinning medicines or who have an allergy to hyaluronic acid, lidocaine or other local anaesthetics. Caution if you take medicines that prolong bleeding time. Treatment lasts 12-24 months. Restylane has not been tested in pregnant or breast-feeding women. ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN. Galderma, Auckland. Distributed by Healthcare Logistics, Auckland


3. Restylane® Skinboosters is a gel containing hyaluronic acid that is injected into or below the skin to improve skin structure,
hydration and elasticity. Restylane® Skinboosters is a medical device class III that has risks and benefits. Do not use in patients with bleeding disorders, or in patients taking blood thinning medicines. Do not inject intravascularly, where there is active disease, inflammation, infection, or tumours near the intended treatment site Possible side effects are injection site effects like swelling, bruising, and tenderness and inflammation. Treatment usually lasts 6-12 months. Product and treatment costs will apply. Consult your cosmetic practitioner for further information. Further product details can also be found in the full product information. Galderma,  Auckland.

4.Sculptra® is a poly-L-lactic acid implant liquid that is injected by a healthcare professional into or below the skin to increase volume
of depressed areas, particularly to correct skin depressions. Class III Medical Device. Sculptra® may also be used for large volume restoration and/or correction of the signs of facial fat loss. Sculptra has risks and benefits. Sculptra® treatment may result in injection site reactions and pain. Ask your healthcare professional to explain the range of possible side effects and tell them if any side effects concern you. Sculptra® should not be injected into skin that is inflamed or infected. Exposure to excessive sunlight or UV lamp exposure should be avoided until redness or swelling has resolved. Sculptra® is not recommended for people taking blood thinning medicines and has not been tested in pregnant or breast-feeding women or those aged under 18 years. Lasts for  12-25 months ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN. Galderma Australia, Sydney. Distributed by Healthcare Logistics Auckland.

5. BELKYRA® injection is a prescription medicine containing 10 mg/mL deoxycholic acid. It is used for the improvement in the
appearance of moderate to severe convexity or fullness associated with fat below the jaws in adults. Do not use in people allergic to this medicine, with infection at site of injection, pregnancy, and lactation. Possible side effects include headaches, difficulty  swallowing, nausea, skin tightness, hypertension, injection site bruising/pain/swelling/numbness/redness/tingling/hardness/itching/discolouration/formation of small areas of hardness/warmth and injection site nerve injury. BELKYRA® treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines  Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your  doctor. Note: Results from BELKYRA® treatment usually last up to 4 years. Allergan New Zealand Limited, Auckland.


6. TEOSYAL RHA® 1, TEOSYAL RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 1, TEOSYAL® PURESENSE REDENSITY 2, TEOSYAL PURESENSE KISS®, TEOSYAL® PURESENSE GLOBAL ACTION, TEOSYAL® PURESENSE DEEP LINES, TEOSYAL® PURESENSE ULTIMATE and TEOSYAL® PURESENSE ULTRA DEEP TEOSYAL KISS® , RHA KISS® , TEOSYAL®  MESO, TEOSYAL® GLOBAL ACTION, TEOSYAL® DEEP LINES, , TEOSYAL® ULTIMATE and TEOSYAL® ULTRA DEEP are trademark of the firm TEOXANE SA.

These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride They are class III medical devices.
Caution for people on blood thinning medicines. Local side effects: inflammatory reactions (redness, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, disorders of pigmentation in skin and hair, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke. Lasts 9 -12 months.
Please consult your doctor pharmacist for more information.
Please refer to instructions for use, local distributor. Healthcare Logistics, Auckland.


 

bottom of page